Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology

Journal of Neurochemistry

Volumn , Issue , 2016, Pages 275-289

  Tyson, Trevor ^a   Steiner, Jennifer A ^a   Brundin, Patrik ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

autophagy; exocytosis; homeostasis; Parkinson's disease; prion; synuclein

Indexed keywords

ALPHA SYNUCLEIN; PRION PROTEIN;

AUTOPHAGY; CELL SPREADING; CELL STRESS; CELL SURVIVAL; CELL TRANSFER; CORPUS STRIATUM; EXOCYTOSIS; HUMAN; NERVE CELL; NERVE ENDING; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MISFOLDING; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN TRANSPORT; REVIEW; SUBSTANTIA NIGRA; SUMOYLATION; UBIQUITINATION;

EID: 85028261236     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13449     Document Type: Review

References (183)

1. Agarraberes F. A. and Dice J. F. (2001) A molecular chaperone complex at the lysosomal membrane is required for protein translocation. J. Cell Sci. 114, 2491–2499.
2. Alvarez-Erviti L., Seow Y., Schapira A. H., Gardiner C., Sargent I. L., Wood M. J. A. and Cooper J. M. (2011) Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol. Dis. 42, 360–367.
3. Andrews N. W. (2000) Regulated secretion of conventional lysosomes. Trends Cell Biol. 10, 316–321.
4. Arighi C. N., Hartnell L. M., Aguilar R. C., Haft C. R. and Bonifacino J. S. (2004) Role of the mammalian retromer in sorting of the cation-independent mannose 6-phosphate receptor. J. Cell Bio. 165, 123–133.
5. Baba M., Nakajo S., Tu P. H., Tomita T., Nakaya K., Lee V. M., Trojanowski J. Q. and Iwatsubo T. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879–884.
6. Bae E.-J., Yang N.-Y., Song M., et al. (2014) Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein. Nat. Commun. 5, 4755.
7. Bartels T., Choi J. G. and Selkoe D. J. (2011) α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107–110.
8. Beach T. G., Adler C. H., Lue L. F., Sue L. I., Bachalakuri J., Henry-Watson J., Sasse J., Boyer S., Shirohi S. and Brooks R. (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117, 613–634.
9. Bonifacino J. S. and Hurley J. H. (2008) Retromer. Curr. Opin. Cell Biol. 20, 427–436.
10. Bonifacino J. S. and Rojas R. (2006) Retrograde transport from endosomes to the trans-Golgi network. Nat. Rev. Mol. Cell Biol. 7, 568–579.
11. Braak H. and del Tredici K. (2008) Invited Article: nervous system pathology in sporadic Parkinson disease. Neurology 70, 1916–1925.
12. Braak H., Del Tredici K., Rub U., de Vos R. A. I., Steur E. and Braak E. (2003a) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197–211.
13. Braak H., R b U., Gai W. P. and Del Tredici K. (2003b) Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural. Transm. 110, 517–536.
14. Braak H., Ghebremedhin E., Rüb U., Bratzke H. and del Tredici K. (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318, 121–134.
15. Braak H., Sastre M. and del Tredici K. (2007) Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol. 114, 231–241.
16. Bruns C., McCaffery J. M., Curwin A. J., Duran J. M. and Malhotra V. (2011) Biogenesis of a novel compartment for autophagosome-mediated unconventional protein secretion. J. Cell Biol. 195, 979–992.
17. Burré J. (2015) The synaptic function of a-synuclein. J Parkinsons Dis. 4, 699–713.
18. Burré J., Sharma M., Tsetsenis T., Buchman V., Etherton M. R. and Südhof T. C. (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663–1667.
19. Burré J., Sharma M. and Südhof T. C. (2014) α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc. Natl Acad. Sci. USA 111, E4274–E4283.
20. Chandra S., Gallardo G., Fernández-Chacón R., Schlüter O. M. and Südhof T. C. (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123, 383–396.
21. Chaudhuri K. R., Yates L. and Martinez-Martin P. (2005) The non-motor symptom complex of Parkinson's disease: a comprehensive assessment is essential. Curr. Neurol. Neurosci. Rep. 5, 275–283.
22. Chiang H. L., Terlecky S. R., Plant C. P. and Dice J. F. (1989) A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. Science 246, 382–385.
23. Chu Y., Dodiya H., Aebischer P., Olanow C. W. and Kordower J. H. (2009) Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis. 35, 385–398.
24. Cuervo A. M. and Dice J. F. (1996) A receptor for the selective uptake and degradation of proteins by lysosomes. Science 273, 501–503.
25. Cuervo A. M., Stefanis L., Fredenburg R., Lansbury P. T. and Sulzer D. (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292–1295.
26. Cuervo A. M., Wong E. S. P. and Martinez-Vicente M. (2010) Protein degradation, aggregation, and misfolding. Mov. Disord. 25, S49–S54.
27. Cullen V., Lindfors M., Ng J. et al. (2009) Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol. Brain 2, 5.
28. Danzer K. M., Kranich L. R., Ruf W. P., Cagsal-Getkin O., Winslow A. R., Zhu L., Vanderburg C. R. and McLean P. J. (2012) Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 7, 42.
29. Dargemont C. and Ossareh-Nazari B. (2012) Cdc48/p97, a key actor in the interplay between autophagy and ubiquitin/proteasome catabolic pathways. Biochim. Biophys. Acta 1823, 138–144.
30. Decressac M., Mattsson B., Weikop P., Lundblad M., Jakobsson J. and Björklund A. (2013) TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc. Natl Acad. Sci. USA 110, E1817–E1826.
31. Dehay B. (2014) Alpha-synuclein spreading in Parkinson's disease. Front. Neuroanat. 8, 159.
32. Dettmer U., Selkoe D. and Bartels T. (2015) New insights into cellular homeostasis in health and disease. Curr. Opini. Neurobiol. 36, 15–22.
33. Dice J. F. (1990) Peptide sequences that target cytosolic proteins for lysosomal proteolysis. Trends Biochem. Sci. 15, 305–309.
34. Djelloul M., Holmqvist S., Boza-Serrano A., Azevedo C., Yeung M. S., Goldwurm S., Frisén J., Deierborg T. and Roybon L. (2015). Alpha-synuclein expression in the oligodendrocyte lineage: an in vitro and in vivo study using rodent and human models. Stem Cell Reports 5, 174–184.
35. Dorval V. and Fraser P. E. (2006) Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J. Biol. Chem. 281, 9919–9924.
36. Dufty B. M., Warner L. R., Hou S. T., Jiang S. X., Gomez-Isla T., Leenhouts K. M., Oxford J. T., Feany M. B., Masliah E. and Rohn T. T. (2007) Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. 170, 1725–1738.
37. Dunning C. J. R., Reyes J. F., Steiner J. A. and Brundin P. (2011) Can Parkinson's disease pathology be propagated from one neuron to another? Prog. Neurobiol. 97, 205–219.
38. El-Agnaf O. M., Jakes R., Curran M. D., Middleton D., Ingenito R., Bianchi E., Pessi A., Neill D. and Wallace A. (1998) Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 440, 71–75.
39. El-Agnaf O. M. A., Salem S. A., Paleologou K. E. et al. (2003) Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17, 1945–1947.
40. Fader C. M., Sánchez D., Furlán M. and Colombo M. I. (2008) Induction of autophagy promotes fusion of multivesicular bodies with autophagic vacuoles in k562 cells. Traffic 9, 230–250.
41. Fahn S. (2003) Description of Parkinson's disease as a clinical syndrome. Ann. N. Y. Acad. Sci. 991, 1–14.
42. Fellner L., Irschick R., Schanda K., Reindl M., Klimaschewski L., Poewe W., Wenning G. K. and Stefanova N. (2013) Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia 61, 349–360.
43. Follett J., Norwood S. J., Hamilton N. A. et al. (2014) The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer. Traffic 15, 230–244.
44. Freeman D., Cedillos R., Choyke S. et al. (2013) Alpha-Synuclein Induces Lysosomal Rupture and Cathepsin Dependent Reactive Oxygen Species Following Endocytosis. PLoS ONE 8, e62143.
45. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M. S., Shen J., Takio K. and Iwatsubo T. (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160–164.
46. Games D., Valera E., Spencer B. et al. (2014) Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J. Neurosci. 34, 9441–9454.
47. George S. and Brundin P. (2015) Immunotherapy in Parkinson's Disease: micromanaging Alpha-Synuclein Aggregation. J. Parkinsons Dis. 5, 413–424.
48. George J. M., Jin H., Woods W. S. and Clayton D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361–372.
49. George S., Mok S. S., Nurjono M., Ayton S., Finkelstein D. I., Masters C. L., Li Q.-X. and Culvenor J. G. (2010) α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment. J. Mol. Neurosci. 42, 243–254.
50. George S., Rey N. L., Reichenbach N., Steiner J. A. and Brundin P. (2013) α-synuclein: the long distance runner. Brain Pathol. 23, 350–357.
51. Giasson B. I., Duda J. E., Murray I. V., Chen Q., Souza J. M., Hurtig H. I., Ischiropoulos H., Trojanowski J. Q. and Lee V. M. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985–989.
52. Ginns E. I., Mak S. K.-K., Ko N. et al. (2014) Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction. Mol. Genet. Metab. 111, 152–162.
53. Goedert M., Spillantini M. G., Serpell L. C., Berriman J., Smith M. J., Jakes R. and Crowther R. A. (2001) From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases. Philos. T Roy. Soc. B 356, 213–227.
54. Gomez T. S. and Billadeau D. D. (2009) A FAM21-containing WASH complex regulates retromer-dependent sorting. Dev. Cell 17, 699–711.
55. Gousset K., Schiff E., Langevin C. et al. (2009) Prions hijack tunnelling nanotubes for intercellular spread. Nat. Cell Biol. 11, 328–336.
56. Halliday G., Hely M., Reid W. and Morris J. (2008) The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol. 115, 409–415.
57. Hansen C., Angot E., Bergström A.-L. et al. (2011) α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121, 715–725.
58. Hawkes C. H., Del Tredici K. and Braak H. (2007) Parkinson's disease: a dual-hit hypothesis. Neuropathol. Appl. Neurobiol. 33, 599–614.
59. Hayashi-Nishino M., Fujita N., Noda T., Yamaguchi A., Yoshimori T. and Yamamoto A. (2009) A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation. Nat. Cell Biol. 11, 1433–1437.
60. Hishikawa N., Hashizume Y., Yoshida M. and Sobue G. (2001) Widespread occurrence of argyrophilic glial inclusions in Parkinson's disease. Neuropathol. Appl. Neurobiol. 27, 362–372.
61. Hodara R., Norris E. H., Giasson B. I., Mishizen-Eberz A. J., Lynch D. R., Lee V. M. Y. and Ischiropoulos H. (2004) Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J. Biol. Chem. 279, 47746–47753.
62. Holmes B. B., Devos S. L., Kfoury N. et al. (2013) Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl Acad. Sci. USA 110, 3138–3147.
63. Hruska K. S., LaMarca M. E., Scott C. R. and Sidransky E. (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum. Mutat. 29, 567–583.
64. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M. and Hashizume Y. (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 106, 518–526.
65. Inglis K. J., Chereau D., Brigham E. F. et al. (2009) Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J. Biol. Chem. 284, 2598–2602.
66. Iwai A., Masliah E., Yoshimoto M., Ge N. and Flanagan L. (1995) The precursor protein of non-Aß component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467–475.
67. Iwata A., Maruyama M., Akagi T., Hashikawa T., Kanazawa I., Tsuji S. and Nukina N. (2003) Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum. Mol. Gen. 12, 2625–2635.
68. Jang A., Lee H.-J., Suk J.-E., Jung J.-W., Kim K. P. and Lee S.-J. (2010) Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J. Neurochem. 113, 1263–1274.
69. Jellinger K. A. (2008) A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol. 116, 1–16.
70. Jenco J. M., Andrew R., Brenda Daniels A. and Morris A. J. (1998) Regulation of phospholipase D2:? selective inhibition of mammalian phospholipase D isoenzymes by a- and ß-synucleins†. Biochemistry 37, 4901–4909.
71. Joo S. H., Kwon K. J., Kim J. W., Kim J. W., Hasan M. R., Lee H.-J., Han S.-H. and Shin C. Y. (2010) Regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by alpha-synuclein in rat primary glial cells. Neurosci. Lett. 469, 352–356.
72. Kim Y. M., Jang W. H., Quezado M. M., Oh Y., Chung K. C., Junn E. and Mouradian M. M. (2011) Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation. J. Neurol. Sci. 307, 157–161.
73. Kim K. S., Choi Y. R., Park J. Y., Lee J. H., Kim D. K., Lee S. J., Paik S. R., Jou I. and Park S. M. (2012) Proteolytic cleavage of extracellular a-synuclein by plasmin: implications for Parkinson's disease. J. Biol. Chem. 287, 24862–24872.
74. Kim C., Ho D.-H., Suk J.-E. et al. (2013) Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 4, 1562.
75. Klegeris A., Pelech S., Giasson B. I., Maguire J., Zhang H., McGeer E. G. and McGeer P. L. (2008) α-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol. Aging 29, 739–752.
76. Klinger S., Siupka P. and Nielsen M. (2015) Retromer-mediated trafficking of transmembrane receptors and transporters. Membranes 5, 288–306.
77. Kong S. M. Y., Chan B. K. K., Park J.-S. et al. (2014) Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomes. Hum. Mol. Gen. 23, 2816–2833.
78. Kordower J. H., Chu Y., Hauser R. A., Freeman T. B. and Olanow C. W. (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504–506.
79. Kraft C. and Martens S. (2012) Mechanisms and regulation of autophagosome formation. Curr. Opin. Cell Biol. 24, 496–501.
80. Kramer M. L. and Schulz-Schaeffer W. J. (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci. 27, 1405–1410.
81. Krumova P., Meulmeester E., Garrido M. et al. (2011) Sumoylation inhibits α-synuclein aggregation and toxicity. J. Cell Biol. 194, 49–60.
82. Kurowska Z., Englund E., Widner H., Lindvall O., Li J.-Y. and Brundin P. (2011) Signs of degeneration in 12-22-year old grafts of mesencephalic dopamine neurons in patients with Parkinson's disease. J. Parkinsons Dis. 1, 83–92.
83. Lee H.-J., Patel S. and Lee S.-J. (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 25, 6016–6024.
84. Lee H.-J., Suk J.-E., Bae E.-J., Lee J.-H., Paik S. R. and Lee S.-J. (2008a) Assembly-dependent endocytosis and clearance of extracellular α-synuclein. Int. J. Biochem. Cell Biol. 40, 1835–1849.
85. Lee H.-J., Suk J.-E., Bae E.-J. and Lee S.-J. (2008b) Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem. Biophys. Res. Commun. 372, 423–428.
86. Lee H.-J., Suk J.-E., Patrick C., Bae E.-J., Cho J.-H., Rho S., Hwang D., Masliah E. and Lee S.-J. (2010) Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 285, 9262–9272.
87. Lee H.-J., Cho E.-D., Lee K.-W., Kim J.-H., Cho S.-G. and Lee S.-J. (2013) Autophagic failure promotes the exocytosis and intercellular transfer of α-synuclein. Exp. Mol. Med. 45, e22–e29.
88. Lema Tomé C. M., Tyson T., Rey N. L., Grathwohl S., Britschgi M. and Brundin P. (2012) Inflammation and a-synuclein's prion-like behavior in Parkinson's disease—Is there a link? Mol. Neurobiol. 47, 561–574.
89. Lerner A. and Bagic A. (2008) Olfactory pathogenesis of idiopathic Parkinson disease revisited. Mov. Disord. 23, 1076–1084.
90. Leyk J., Goldbaum O., Noack M. and Richter-Landsberg C. (2015) Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance. J. Mol. Neurosci. 55, 1031–1046.
91. Li W., West N., Colla E. et al. (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl Acad. Sci. USA 102, 2162–2167.
92. Li J.-Y., Englund E., Holton J. L. et al. (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501–503.
93. Li J.-Y., Englund E., Widner H., Rehncrona S., Björklund A., Lindvall O. and Brundin P. (2010) Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov. Disord. 25, 1091–1096.
94. Liu S., Ninan I., Antonova I., Battaglia F., Trinchese F., Narasanna A., Kolodilov N., Dauer W., Hawkins R. D. and Arancio O. (2004) alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J. 23, 4506–4516.
95. Luk K. C., Kehm V. M., Zhang B., O'Brien P., Trojanowski J. Q. and Lee V. M. Y. (2012a) Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative -synucleinopathy in mice. J. Exp. Med. 209, 975–986.
96. Luk K. C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J. Q. and Lee V. M. Y. (2012b) Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949–953.
97. MacLeod D. A., Rhinn H., Kuwahara T. et al. (2013) RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 77, 425–439.
98. Mahul-Mellier A.-L., Fauvet B., Gysbers A. et al. (2014) c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum. Mol. Gen. 23, 2858–2879.
99. Mak S. K., McCormack A. L., Manning-Bog A. B., Cuervo A. M. and Di Monte D. A. (2010) Lysosomal degradation of alpha-synuclein in vivo. J. Biol. Chem. 285, 13621–13629.
100. Manning-Bog A. B., McCormack A. L., Li J., Uversky V. N., Fink A. L. and Di Monte D. A. (2002) The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277, 1641–1644.
101. Martinez-Martin P., Rodriguez-Blazquez C., Kurtis M. M. and Chaudhuri K. R., on Behalf of the NMSS Validation Group (2011) The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov. Disord. 26, 399–406.
102. Martinez-Vicente M., Talloczy Z., Kaushik S. et al. (2008) Dopamine-modified a-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 118, 777–788.
103. Martins-Branco D., Esteves A. R., Santos D., Arduino D. M., Swerdlow R. H., Oliveira C. R., Januario C. and Cardoso S. M. (2012) Ubiquitin proteasome system in Parkinson's disease: a keeper or a witness? Exp. Neurol. 238, 89–99.
104. Masliah E., Rockenstein E., Mante M. et al. (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of lewy body disease. PLoS ONE 6, e19338.
105. Masuda-Suzukake M., Nonaka T., Hosokawa M., Kubo M., Shimozawa A., Akiyama H. and Hasegawa M. (2014) Pathological alpha-synuclein propagates through neural networks. Acta. Neuropathol. Commun. 2, 492.
106. Mbefo M. K., Paleologou K. E., Boucharaba A. et al. (2010) Phosphorylation of synucleins by members of the Polo-like kinase family. J. Biol. Chem. 285, 2807–2822.
107. McGlinchey R. P. and Lee J. C. (2015) Cysteine cathepsins are essential in lysosomal degradation of α-synuclein. Proc. Natl Acad. Sci. USA 112, 9322–9327.
108. Meier B. H. and Böckmann A. (2015) The structure of fibrils from “misfolded” proteins. Curr. Opin. Struct. Biol. 30, 43–49.
109. Mishizen-Eberz A. J., Guttmann R. P., Giasson B. I., Day G. A., Hodara R., Ischiropoulos H., Lee V. M. Y., Trojanowski J. Q. and Lynch D. R. (2003) Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J. Neurochem. 86, 836–847.
110. Mollenhauer B., Trautmann E., Otte B. et al. (2012) α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J. Neural. Transm. 119, 739–746.
111. Mori F., Tanji K., Yoshimoto M., Takahashi H. and Wakabayashi K. (2002) Immunohistochemical comparison of alpha- and beta-synuclein in adult rat central nervous system. Brain Res. 941, 118–126.
112. Mougenot A.-L., Nicot S., Bencsik A., Morignat E., Verchère J., Lakhdar L., Legastelois S. and Baron T. (2012) Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33, 2225–2228.
113. Murray I. V. J., Giasson B. I., Quinn S. M., Koppaka V., Axelsen P. H., Ischiropoulos H., Trojanowski J. Q. and Lee V. M. Y. (2003) Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42, 8530–8540.
114. Nemani V. M., Lu W., Berge V., Nakamura K., Onoa B., Lee M. K., Chaudhry F. A., Nicoll R. A. and Edwards R. H. (2010) Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 66–79.
115. Nilsson P., Loganathan K., Sekiguchi M., Matsuba Y., Hui K., Tsubuki S., Tanaka M., Iwata N., Saito T. and Saido T. C. (2013) Aβ secretion and plaque formation depend on autophagy. Cell Rep. 5, 61–69.
116. Ninkina N., Peters O. M., Connor-Robson N., Lytkina O., Sharfeddin E. and Buchman V. L. (2012) Contrasting effects of α-synuclein and γ-synuclein on the phenotype of cysteine string protein α (CSPα) null mutant mice suggest distinct function of these proteins in neuronal synapses. J. Biol. Chem. 287, 44471–44477.
117. Ogawa K., Yamada T., Tsujioka Y. et al. (2000) Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer”s disease and Parkinson”s disease. Psychiatry Clin. Neurosci. 54, 419–426.
118. Oh Y., Kim Y. M., Mouradian M. M. and Chung K. C. (2011) Human Polycomb protein 2 promotes α-synuclein aggregate formation through covalent SUMOylation. Brain Res. 1381, 78–89.
119. Okochi M., Walter J., Koyama A., Nakajo S., Baba M., Iwatsubo T., Meijer L., Kahle P. J. and Haass C. (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 275, 390–397.
120. Olanow C. W., Perl D. P., DeMartino G. N. and McNaught K. S. (2004) Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol. 3, 496–503.
121. Oueslati A., Schneider B. L., Aebischer P. and Lashuel H. A. (2013) Polo-like kinase 2 regulates selective autophagic a-synuclein clearance and suppresses its toxicity in vivo. Proc. Natl Acad. Sci. USA 1, 3945–3954.
122. Park J.-Y., Paik S. R., Jou I. and Park S. M. (2008) Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease. Glia 56, 1215–1223.
123. Parkkinen L., Pirttila T. and Alafuzoff I. (2008) Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol. 115, 399–407.
124. Paxinou E., Chen Q., Weisse M., Giasson B. I., Norris E. H., Rueter S. M., Trojanowski J. Q., Lee V. M. and Ischiropoulos H. (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21, 8053–8061.
125. Peelaerts W., Bousset L., derVan Perren A., Moskalyuk A., Pulizzi R., Giugliano M., Van den Haute C., Melki R. and Baekelandt V. (2015) a-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340–344.
126. Piper R. C. and Katzmann D. J. (2007) Biogenesis and function of multivesicular bodies. Annu. Rev. Cell Dev. Biol. 23, 519–547.
127. Poehler A.-M., Xiang W., Spitzer P. et al. (2015) Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment. Autophagy 10, 2171–2192.
128. Prusiner S. B., Woerman A. L., Mordes D. A. et al. (2015) Evidence for a-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc. Natl Acad. Sci. USA 112, 5308–5317.
129. Qiao L., Hamamichi S., Caldwell K. A. et al. (2008) Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol. Brain 1, 17.
130. Radford R., Rcom-H'cheo-Gauthier A., Wong M. B. et al. (2015) The degree of astrocyte activation in multiple system atrophy is inversely proportional to the distance to a-synuclein inclusions. Mol. Cell Neurosci. 65, 68–81.
131. Recasens A., Dehay B., Bové J. et al. (2013) Lewy body extracts from parkinson's disease brains trigger a-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 75, 351–362.
132. Reyes J. F., Rey N. L., Bousset L., Melki R., Brundin P. and Angot E. (2014) Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 62, 387–398.
133. Reyes J. F., Olsson T. T., Lamberts J. T., Devine M. J., Kunath T. and Brundin P. (2015) A cell culture model for monitoring α-synuclein cell-to-cell transfer. Neurobiol. Disease 77, 266–275.
134. Rott R., Szargel R., Haskin J., Shani V., Shainskaya A., Manov I., Liani E., Avraham E. and Engelender S. (2008) Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J. Biol. Chem. 283, 3316–3328.
135. Sacino A. N., Brooks M., Thomas M. A. et al. (2014) Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc. Natl Acad. Sci. USA 111, 10732–10737.
136. Sanchez-Guajardo V., Annibali A., Jensen P. H. and Romero-Ramos M. (2013) α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model. J. Neuropathol. Exp. Neurol. 72, 624–645.
137. Schneeberger A., Mandler M. and Mattner F. (2012) Vaccination for Parkinson's disease. Parkinsonism Relat. Disord. 1, 11–13.
138. Seaman M. N. J. (2012) The retromer complex - endosomal protein recycling and beyond. J. Cell Sci. 125, 4693–4702.
139. Sevlever D., Jiang P. and Yen S.-H. C. (2008) Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 47, 9678–9687.
140. Shahpasandzadeh H., Popova B., Kleinknecht A., Fraser P. E., Outeiro T. F. and Braus G. H. (2014) Interplay between sumoylation and phosphorylation for protection against α-synuclein inclusions. J. Biol. Chem. 289, 31224–31240.
141. Shimura H., Schlossmacher M. G., Hattori N., Frosch M. P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K. S. and Selkoe D. J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263–269.
142. Shin Y. (2005) The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates αlpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J. Biol. Chem. 280, 23727–23734.
143. Simonsen A. H., Kuiperij B., Ali El-Agnaf O. M. et al. (2015) The utility of a-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Biomark Med.
144. Spencer B., Potkar R., Trejo M., Rockenstein E., Patrick C., Gindi R., Adame A., Wyss-Coray T. and Masliah E. (2009) Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in α-synuclein models of Parkinson's and lewy body diseases. J. Neurosci. 29, 13578–13588.
145. Spencer B., Michael S., Shen J., Kosberg K., Rockenstein E., Patrick C., Adame A. and Masliah E. (2013) Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD. Mol. Ther. 21, 31–41.
146. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839–840.
147. Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M. and Goedert M. (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469–6473.
148. Stefanis L., Larsen K. E., Rideout H. J., Sulzer D. and Greene L. A. (2001) Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21, 9549–9560.
149. Steiner J. A., Angot E. and Brundin P. (2011) A deadly spread: cellular mechanisms of α-synuclein transfer. Cell Death Differ. 18, 1425–1433.
150. Sung J. Y., Kim J., Paik S. R., Park J. H., Ahn Y. S. and Chung K. C. (2001) Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein. J. Biol. Chem. 276, 27441–27448.
151. Sung J. Y., Park S. M., Lee C. H., Um J. W., Lee H. J., Kim J., Oh Y. J., Lee S. T., Paik S. R. and Chung K. C. (2005) Proteolytic cleavage of extracellular secreted alpha-synuclein via matrix metalloproteinases. J. Biol. Chem. 280, 25216–25224.
152. Tanaka K. and Matsuda N. (2014) Proteostasis and neurodegeneration: the roles of proteasomal degradation and autophagy. Biochim. Biophys. Acta 1843, 197–204.
153. Tanaka M., Kim Y. M., Lee G., Junn E., Iwatsubo T. and Mouradian M. M. (2004) Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 279, 4625–4631.
154. Tanik S. A., Schultheiss C. E., Volpicelli-Daley L. A., Brunden K. R. and Lee V. M. Y. (2013) Lewy body-like a -synuclein aggregates resist degradation and impair macroautophagy. J. Biol. Chem. 288, 15194–15210.
155. Tatebe H., Watanabe Y., Kasai T., Mizuno T., Nakagawa M., Tanaka M. and Tokuda T. (2010) Extracellular neurosin degrades α-synuclein in cultured cells. Neurosci. Res. 67, 341–346.
156. Tenreiro S., Eckermann K. and Outeiro T. F. (2014a) Protein phosphorylation in neurodegeneration: friend or foe? Front. Mol. Neurosci. 7, 42.
157. Tenreiro S., Reimão-Pinto M. M., Antas P. et al. (2014b) Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. PLoS Genet. 10, e1004302.
158. Tetzlaff J. E., Putcha P., Outeiro T. F., Ivanov A., Berezovska O., Hyman B. T. and McLean P. J. (2008) CHIP targets toxic α-synuclein oligomers for degradation. J. Biol. Chem. 283, 17962–17968.
159. Tofaris G. K., Layfield R. and Spillantini M. G. (2001) alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 509, 22–26.
160. Tofaris G. K., Razzaq A., Ghetti B., Lilley K. S. and Spillantini M. G. (2003) Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 278, 44405–44411.
161. Tofaris G. K., Kim H. T., Hourez R., Jung J.-W., Kim K. P. and Goldberg A. L. (2011) Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc. Natl Acad. Sci. USA 108, 17004–17009.
162. Tran H. T., Chung C. H.-Y., Iba M., Bin Z., Trojanowski J. Q., Luk K. C. and Lee V. M. Y. (2014) a-synuclein immunotherapy blocks uptakeand templated propagation of misfolded a-synuclein and neurodegeneration. CellReports 7, 1–29.
163. Tsujimura A., Taguchi K., Watanabe Y., Tatebe H., Tokuda T., Mizuno T. and Tanaka M. (2014) Lysosomal enzyme cathepsin B enhances the aggregate forming activity of exogenous α-synuclein fibrils. Neurobiol. Disease 73C, 244–253.
164. Tucker H. M., Kihiko M., Caldwell J. N. et al. (2000) The plasmin system is induced by and degrades amyloid-beta aggregates. J. Neurosci. 20, 3937–3946.
165. Ulusoy A., Febbraro F., Jensen P. H., Kirik D. and Romero-Ramos M. (2010) Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur. J. Neurosci. 32, 409–422.
166. Ulusoy A., Musgrove R. E., Rusconi R., Klinkenberg M., Helwig M., Schneider A. and Di Monte D. A. (2015) Neuron-to-neuron a-synuclein propagation in vivo is independent of neuronal injury. Acta Neuropathol Commun 3, 13.
167. Van Nostrand W. E. and Porter M. (1999) Plasmin cleavage of the amyloid ß-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 38, 11570–11576.
168. Vermilyea S. C. and Emborg M. E. (2015) α-Synuclein and nonhuman primate models of Parkinson's disease. J. NeurosciMethods 255, 38–51.
169. Vilariño-Güell C., Wider C., Ross O. A. et al. (2011) VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 89, 162–167.
170. Vogiatzi T., Xilouri M., Vekrellis K. and Stefanis L. (2008) Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem. 283, 23542–23556.
171. Volpicelli-Daley L. A., Luk K. C., Patel T. P., Tanik S. A., Riddle D. M., Stieber A., Meaney D. F., Trojanowski J. Q. and Lee V. M. Y. (2011) Exogenous alpha-synuclein fibrils induce lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57–71.
172. Wakabayashi K., Hayashi S., Yoshimoto M., Kudo H. and Takahashi H. (2000) NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol. 99, 14–20.
173. Wang W., Perovic I., Chittuluru J. et al. (2011) A soluble α-synuclein construct forms a dynamic tetramer. Proc. Natl Acad. Sci. USA 108, 17797–17802.
174. Watts J. C., Giles K., Oehler A., Middleton L., Dexter D. T., Gentleman S. M., Dearmond S. J. and Prusiner S. B. (2013) Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl Acad. Sci. USA 110, 19555–19560.
175. Weinreb P. H., Zhen W., Poon A. W., Conway K. A. and Lansbury P. T. (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709–13715.
176. Winslow A. R., Chen C. W., Corrochano S. et al. (2010) α-Synuclein impairs macroautophagy: implications for Parkinson's disease. J. Cell Biol. 190, 1023–1037.
177. Xilouri M., Vogiatzi T., Vekrellis K., Park D. and Stefanis L. (2009) Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS ONE 4, e5515.
178. Yan J.-Q., Yuan Y.-H., Gao Y.-N., Huang J.-Y., Ma K.-L., Gao Y., Zhang W.-Q., Guo X.-F. and Chen N.-H. (2014) Overexpression of Human E46K Mutant α-Synuclein Impairs Macroautophagy via Inactivation of JNK1-Bcl-2 Pathway. Mol. Neurobiol. 50, 685–701.
179. Yu W. H., Dorado B., Figueroa H. Y., Wang L., Planel E., Cookson M. R., Clark L. N. and Duff K. E. (2009) Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am. J. Pathol. 175, 736–747.
180. Yu Z., Xu X., Xiang Z., Zhou J., Zhang Z., Hu C. and He C. (2010) Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS ONE 5, e9956.
181. Zaccai J., Brayne C., McKeith I., Matthews F. and Ince P. G. (2008) Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 70, 1042–1048.
182. Zavodszky E., Seaman M. N. J., Moreau K., Jimenez-Sanchez M., Breusegem S. Y., Harbour M. E. and Rubinsztein D. C. (2014) Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy. Nat. Commun. 5, 3828.
183. Zimprich A., Benet-Pagès A., Struhal W. et al. (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 89, 168–175.